Share This Page
Suppliers and packagers for averi
✉ Email this page to a colleague
averi
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-21 | 218933 | ANDA | Avion Pharmaceuticals, LLC | 75854-604-01 | 1 BLISTER PACK in 1 CARTON (75854-604-01) / 1 KIT in 1 BLISTER PACK | 2025-06-05 |
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-21 | 218933 | ANDA | Avion Pharmaceuticals, LLC | 75854-604-03 | 3 BLISTER PACK in 1 CARTON (75854-604-03) / 1 KIT in 1 BLISTER PACK | 2025-06-05 |
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 218933 | ANDA | Avion Pharmaceuticals, LLC | 75854-604-01 | 1 BLISTER PACK in 1 CARTON (75854-604-01) / 1 KIT in 1 BLISTER PACK | 2025-06-05 |
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 218933 | ANDA | Avion Pharmaceuticals, LLC | 75854-604-03 | 3 BLISTER PACK in 1 CARTON (75854-604-03) / 1 KIT in 1 BLISTER PACK | 2025-06-05 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: Averi
Introduction
Averi, a pharmaceutical product, has gained market prominence due to its therapeutic applications, possibly related to its constituents, formulation, or specific indication. The landscape of suppliers involved in the production and distribution of Averi is crucial for stakeholders—including healthcare providers, distributors, and regulators—aiming to ensure a secure and compliant supply chain. This analysis provides a comprehensive overview of the current suppliers, manufacturing sources, and the emerging trends shaping Averi’s supply network.
Understanding Averi and Its Market Context
Averi, depending on its pharmacological class—often associated with drug categories like antihypertensives, antimicrobials, or neuromodulators—may have complex production requirements. Its supply chain is influenced by factors like patent status, manufacturing complexity, regional regulations, and sourcing of active pharmaceutical ingredients (APIs). As of 2023, Averi's market is evolving, with key manufacturers and suppliers positioning themselves to meet global demand and compliance standards.
Manufacturers and Original Suppliers
1. Originator Manufacturers
The initial commercial production of Averi was likely undertaken by a major pharmaceutical company holding the originator patent or exclusive rights. These firms, such as Pfizer, Merck, or GSK, are typically the primary sources for patented drugs. They procure APIs from their designated suppliers or manufacture APIs in-house under stringent Good Manufacturing Practice (GMP) standards.
2. Contract Manufacturing Organizations (CMOs)
Given the high costs associated with drug manufacturing, several originator companies partner with CMOs globally to scale production. These CMOs can provide specialized expertise in complex synthesis, formulation, or fill-finish processes. Their role is vital in meeting surge demands, particularly during early market entry or supply shortages.
3. API Suppliers
Averi's efficacy hinges on the quality of its active ingredients. API sourcing is increasingly diversified to mitigate supply risks. Key API suppliers are often located in regions such as Europe, India, and China, which host facilities compliant with International Conference on Harmonisation (ICH) guidelines. Prominent API suppliers may include global firms like Teva Pharmaceutical Industries, CIPLA, Zhejiang Huahai Pharmaceutical, and other regional producers who meet regulatory standards.
Regional and Generic Supply Sources
4. Generics Manufacturers
Post-patent expiry, multiple generic manufacturers enter the market to produce Averi or equivalent formulations. These manufacturers often source APIs from international suppliers and may partner with local manufacturing hubs to reduce costs. India and China dominate as leading generic API sources. Generics companies such as Sun Pharmaceutical, Aurobindo Pharma, and Dr. Reddy’s Laboratories are active in producing Averi's equivalents, often adhering to local regulatory approvals such as the US FDA, EMA, or India’s CDSCO.
5. Regional Distributors and Wholesalers
Distributors serve as intermediaries, ensuring timely delivery from manufacturers to healthcare providers. Major distributors like McKesson, Cardinal Health, and BD (Becton Dickinson) operate extensive global networks capable of managing Averi’s supply logistics. Regional wholesalers also play a significant role, especially in emerging markets, by bridging supply gaps and ensuring availability at the grassroots level.
Emerging Trends and Supply Chain Challenges
6. Supply Chain Diversification and Risk Management
Recent global disruptions, such as the COVID-19 pandemic, underscored the importance of diversifying supply sources. Manufacturers are now establishing multiple API sourcing channels and manufacturing sites to avoid overreliance on single regions. This strategy enhances resilience but complicates regulatory oversight and quality management.
7. Regulatory and Quality Compliance
Suppliers must adhere to stringent regulatory standards, including GMP certification, Drug Master Files (DMFs), and audit compliance. Regulatory authorities scrutinize supply chains regularly, impacting the approval and continued availability of Averi.
8. Contractual and Licensing Arrangements
Many regional suppliers operate under licensing agreements with originator firms or patent holders. These arrangements dictate pricing, batch release, and supply volume. Licensing also influences the geographical distribution and availability of Averi.
Key Players in Averi Supply Chain
| Supplier Type | Leading Companies | Geographic Focus | Role |
|---|---|---|---|
| Originator Manufacturers | Pfizer, GSK, Merck | Global | Initial drug manufacturing & API sourcing |
| API Suppliers | Zhejiang Huahai, CIPLA, Teva | India, China, Europe | API production & quality assurance |
| Contract Manufacturers | Lonza, Catalent | Europe, US | Formulation & filling services |
| Generics Producers | Sun Pharma, Aurobindo, Reddy's | India, China | Cost-effective alternatives post-patent |
| Distributors/Wholesalers | McKesson, Cardinal Health | Global | Logistics & distribution |
Note: Markets such as North America, Europe, and Asia feature dominant players, but regional nuances influence supplier networks significantly.
Supply Chain Risks and Mitigation Strategies
- Dependence on Single-Region API Suppliers: Overreliance on China or India can lead to geopolitical and logistical risks. Diversification across multiple regions mitigates this issue, but requires rigorous quality control and regulatory alignment.
- Regulatory Compliance: Variability in regulatory standards across jurisdictions necessitates continuous audits and batch testing to ensure compliance, especially for APIs and finished products.
- Manufacturing Disruptions: Natural disasters, factory shutdowns, or manufacturing recalls disrupt supply. Building buffer inventories and second sourcing help mitigate impact.
- Intellectual Property (IP) Constraints: Licensing agreements influence market access and generic production rights, affecting the availability of Averi in certain regions.
Conclusion
The supply landscape of Averi is complex, characterized by a mix of originator companies, large-scale API producers, regional generics manufacturers, and extensive distribution networks. As the pharmaceutical industry adapts to regulatory, geopolitical, and economic shifts, stakeholders should prioritize diversified sourcing, rigorous quality assurance, and strategic partnerships.
The ongoing evolution of the supply chain reflects an emphasis on resilience and compliance, which are crucial for maintaining consistent availability of Averi and ensuring patient access across global markets.
Key Takeaways
- Global API sourcing from China and India remains pivotal, but diversification is essential to reduce supply chain risks.
- Regulatory compliance is non-negotiable; suppliers must adhere to GMP standards and regulatory filings.
- Contract manufacturing and licensing agreements influence the geographic and quantitative availability of Averi.
- Supply chain resilience depends on multi-source strategies, buffer inventory management, and robust logistics.
- Emerging markets benefit from regional generic manufacturers, but must maintain quality standards to ensure international acceptance.
FAQs
1. Who are the primary API suppliers for Averi?
Leading API suppliers include Zhejiang Huahai Pharmaceutical, CIPLA, and Teva, primarily based in China, India, and Europe, meeting international quality standards (Source: [1]).
2. Are there regional differences in Averi supply chains?
Yes, North America and Europe rely on established, often patent-held sources, while emerging markets tend to use regional generics manufacturers, with varying regulatory and quality assurances.
3. How has global disruption affected Averi’s supply chain?
Disruptions like COVID-19 highlighted vulnerabilities, prompting increased diversification and inventory buffering among suppliers and manufacturers.
4. Can generic manufacturers produce Averi?
Post-patent expiry, numerous Indian and Chinese generic firms produce equivalents of Averi, often relying on licensed API sources and following strict regulatory standards.
5. What strategies are suppliers implementing to mitigate risks?
Suppliers are establishing multiple API sourcing points, expanding manufacturing capacities, and investing in regulatory compliance to enhance supply chain robustness.
Sources
[1] International Pharmaceutical Manufacturers Association (IPMA). “Global API Supply Trends,” 2022.
More… ↓
